{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-001514","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.907565+00:00","generated_at":"2026-06-04T10:24:17.960905+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MiNK Therapeutics reports FY2023 net loss $22.5M; cash $3.4M at year-end","bullets":["Net loss for 2023 was $22.5M ($0.65/share) vs. $28.0M ($0.83/share) in 2022.","Cash and cash equivalents $3.4M at Dec 31, 2023; received $5M post-year-end from Agenus convertible note.","Launched Phase 2 trial of agenT-797 with botensilimab/balstilimab/chemo in 2L gastroesophageal cancers.","Entered collaboration with Immunoscape to develop TCR-based therapies against novel targets.","Nature Communications publication showed >70% survival in ARDS patients on mechanical ventilation with agenT-797."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-001514","json":"https://secwatch.observer/filing/0001171843-24-001514.json","markdown":"https://secwatch.observer/filing/0001171843-24-001514.md","text":"https://secwatch.observer/filing/0001171843-24-001514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000117184324001514/0001171843-24-001514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000117184324001514/f8k_032124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T10:24:17.960905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a44bbef66df4c213d4ad3ebc01a024750bfc4bad","claim":"MiNK Therapeutics, Inc. reported fourth quarter and full-year 2023 results: net income Net loss for the year ended December 31, 2023 was $22.5 million, or $0.65 per share, EPS $0.65.","evidence_excerpt":"MiNK Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840229/000117184324001514/0001171843-24-001514-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full-year 2023"},{"label":"Net income","value":"Net loss for the year ended December 31, 2023 was $22.5 million, or $0.65 per share"},{"label":"EPS","value":"$0.65"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}